Business Context and Reporting Period
This Form 8-K was filed by Skye Bioscience, Inc. on October 14, 2022. The report details a Third Amendment to the Arrangement Agreement with Emerald Health Therapeutics, Inc. (EHT) and the execution of a new loan agreement. Skye is in the process of acquiring all outstanding common shares of EHT via a plan of arrangement under British Columbia law.
Key Financial Metrics and Agreements
- Loan Amount: USD $700,000 borrowed from EHT.
- Interest Rate: 12% per annum simple interest, reducing to 5% per annum upon the closing of the Arrangement Agreement.
- Maturity Date: The earlier of October 17, 2023, or December 31, 2022 (if the Arrangement Agreement is terminated).
- Use of Proceeds: General working capital purposes.
- Security: The loan is unsecured.
- Revenue/Profit/Cash Flow: The filing text does not provide a clear value for revenue, profit, cash flow, margins, or existing debt levels outside of the new loan.
Material Changes and Transaction Status
The primary material change is the extension of the "Outside Date" for the acquisition of EHT to November 15, 2022, or a later date agreed upon in writing. Both companies' stockholders have approved the transaction, and it has received approval from the Supreme Court of British Columbia. The closing is now expected in early to mid-November 2022, pending conditional listing approval from the Canadian Securities Exchange.
Outlook, Risks, and Contingencies
Management indicates continued work toward satisfying remaining closing conditions. A key contingency is the requirement for Skye to obtain conditional listing approval from the Canadian Securities Exchange. The loan agreement includes an Event of Default clause that triggers a higher interest rate (Default Rate) and includes insolvency as a default event. Skye obtained a waiver from Emerald Health Sciences, Inc. to incur this debt under its existing credit facility.
Investor Verification Checklist
- Verify the status of the conditional listing approval from the Canadian Securities Exchange.
- Confirm the expected closing date of the Arrangement Agreement (early to mid-November 2022).
- Review the full text of the Third Amendment (Exhibit 10.1) and Loan Agreement (Exhibit 10.2) for specific covenants and default thresholds.
- Monitor whether the Arrangement Agreement is terminated before December 31, 2022, which would accelerate the loan maturity.